

Supplemental Digital Content. Table S1. Relationship between clinical parameters and extension (UC) disease in North American and Chilean IBD patients. a) Continuous variables (Mann-Whitney U test); b) Categorical variables (Fisher's exact test).

a)

Mann-Whitney U tests	Disease Location		
Variable	E1	E2	E3
Age at Diagnosis	-	0.315	0.508
White Cells	-	0.800	0.591
Plateles	-	0.768	0.079
Albumin	-	1.000	0.026
Hemoglobin	-	0.015	0.511
CRP	-	0.269	0.488
Duration of Disease	-	1.000	0.082

b)

Fisher's exact tests	Disease Location		
Variable	E1	E2	E3
Family history of IBD	-	1.000	1.000
Sex	-	0.007	0.134
Hospitalization for IBD	-	0.108	0.809
Smoking	-	1.000	0.048
Prior history of esterooids use	-	0.183	0.644
Prior history of immunomodulators use	-	0.628	0.041
Prior history of biological therapy use	-	0.093	0.000
History of discontinuation or anti-TNF failure	-	0.129	0.000
Naive anti-TNF	-	0.007	0.000
Current esterooids therapy	-	1.000	0.107
Current biological therapy	-	0.086	0.000
Current anti-TNF therapy	-	0.268	0.008
Current immunomodulator use	-	0.384	0.386

Supplemental Digital Content. Table S2. Relationship between clinical parameters and location (CD) disease in North American and Chilean IBD patients. a) Continuous variables (Mann-Whitney U test); b) Categorical variables (Fisher's exact test).

a)

Mann-Whitney U tests	Disease Location		
Variable	L1	L2	L3
Age at Diagnosis	0.115	0.023	0.782
White Cells	1.000	0.208	0.213
Plateles	0.706	0.658	0.275
Albumin	0.495	0.677	0.005
Hemoglobin	0.261	0.246	0.207
CRP	0.152	0.482	0.480
Duration Disease	1.000	0.124	0.890

b)

Fisher's exact tests	Disease Location		
Variable	L1	L2	L3
Family history of IBD	1.000	0.072	0.335
Sex	1.000	0.099	0.721
Hospitalization for IBD	1.000	1.000	0.086
Smoking	1.000	1.000	0.651
Prior history of esterooids use	1.000	0.556	0.601
Prior history of immunomodulators use	0.447	0.281	0.688
Prior history of biological therapy use	0.079	0.006	0.004
History of discontinuation or anti-TNF failure	0.284	0.002	0.037
Naive anti-TNF	0.111	0.012	0.001
Current esterooids therapy	1.000	0.563	0.398
Current biological therapy	0.053	0.006	0.005
Current anti-TNF therapy	0.032	0.223	0.157
Current immunomodulator use	0.521	0.589	0.732

Supplemental Digital Content. Table S3. Proportion of patients with Crohn’s disease undergoing biological therapies according to localization and center.

L1 (Ileal)	Current biological therapy		p-Value
Center	No	Yes	
USA	0	2	0.053
Chile	15	3	
L2 (Colonic)	Current biological therapy		p-Value
Center	No	Yes	
USA	0	4	0.006
Chile	27	8	
L3 (ileocolonic)	Current biological therapy		p-Value
Center	No	Yes	
USA	3	14	0.005
Chile	11	5	